May 12, 2015
A California federal judge signed off on a deal Tuesday to resolve claims brought by a unit of Par Pharmaceutical Inc. accusing Hospira Inc. of falsely marketing its products as being comparable to Par's FDA-approved version of the allergy treatment epinephrine.
October 08, 2014
A California federal judge on Tuesday trimmed misleading label claims from Par Sterile Products LLC’s suit against makers of epinephrine not approved by the U.S. Food and Drug Administration but allowed false advertising claims to proceed, citing the U.S. Supreme Court's Pom ruling, which found that FDA regulations do not preclude Lanham Act claims.
September 22, 2014
Par Sterile Products LLC urged a California federal judge Monday to keep alive claims that Hospira Inc. and two makers of non-U.S. Food and Drug Administration-approved epinephrine falsely marketed their products as comparable to Par's FDA-approved version of the allergy treatment, saying he needn’t interpret FDA regulations to hear the case.